Allergic asthma is mainly characterized by allergen-induced IAR (immediate airway response) and LAR (late airway response). In regards to the results of lung tissue histology and bronchoalveolar lavage luid analysis, it was con irmed that there is the existence of a casual relationship of eosinophil and other in lammatory cell in iltration in bronchial sub-mucosa in the mechanism of LAR. This investigation aimed to examine the antiasthmatic effect of novel adjuvant therapeutic regimens using a low dose of potent glucocorticoid receptor agonist i.e., Dexamethasone, along with iNOS inhibitor i.e., Aminoguanidine in a both acute and chronic murine model of asthma. Female BALB/c mice of 8 weeks of age were taken and divided into 6 experimental groups i.e. normal control, OVA control, aminoguanidine (200mg/kg), combination of aminoguanidine (200mg/kg) along with dexamethasone (0.03mg/kg), low dose dexamethasone (0.03mg/kg) and Dexamethasone (0.1mg/kg) treated group. After sensitization and introduction of drugs, mice were sacri iced by cervical dislocation and bronchoalveolar lavage (BAL) luid analyzed. The result of this study stated that there is a signi icant reduction in the levels of in lammatory cytokines in combination-treated animals with respect to alone dexamethasone, which may be due to the synergistic effect of aminoguanidine and dexamethasone. From histopathological evidence, it can be concluded that combination treatment having a better lung adaptation mechanism and can improve the condition aggressively. The indings of the study throw some light on an additive therapeutic regimen of aminoguanidine can have a better impact with glucocorticoids.
INTRODUCTION
Allergic asthma is mainly characterized by allergeninduced immediate airway response (IAR) and late airway response (LAR). It remains a complicated disorder of the airways resultant of in lammation. A hallmark feature of asthma is the presence and activation of in lammatory cells in the airways, notably eosinophils, basophils, mast cells, and T lymphocytes, and stimulation of structural/resident cells, including those of the airway epithelium, ibroblasts, smooth muscle, goblet cell hyperplasia, ibroblasts and TGF-β1 plays an important role in such condition (Duvernelle et al., 2003) . Histopathological evaluation and analysis of bronchoalveolar lavage luid (BALF) of lung tissue revealed that the in iltration of eosinophils and other in lammatory cells into the bronchial submucosa mainly responsible for LAR (Monchy et al., 1985) . In lammatory mediators like pro-in lammatory cytokines, nitric oxide (NO) and cysteinyl leukotrienes (Cys LTs) involved in a decisive role of establishing LAR (Meurs et al., 2003) . Glucocorticoids, along with B2 agonist are widely used to treat various in lammatory lung diseases (Simons, 1997; Jonasson, 2000) . Glucocorticoids exert its mechanism through the glucocorticoid receptor (GR) by in lecting either repress (transrepression) or induce (transactivate) gene transcription. In asthma, there is needed long term therapy of inhaled glucocorticoids for its local anti-in lammatory effect, but which can goes to the systemic circulation through the lungs and produces its side effects (Wolthers and Allen, 2002; Randell et al., 2003) .
Like all other asthmatic mediators, it has been reported that in asthma high amount of nitric oxide (NO) is produced by inducible nitric oxide synthase (iNOS) induced by bacterial products and cytokines, and this NO acts as a regulatory and proin lammatory mediator (Agard et al., 2009) . Elevated Nitric oxide (NO) levels are evidence of upregulated iNOS expression in the airways of asthmatics. The use of a selective iNOS inhibitor signi icantly reduces NO exhaled by asthmatics (Crater et al., 1999) . It is reported that iNOS-de icient mice shown less prone to Allergic in lammation in the lungs (Xiong et al., 1999) . NO has distinct effects on the immune system and effectively modulates in lammatory responses. It suppresses T cell proliferation and Th1 cytokine production in mice and thus favors the development of Th2 response with eosinophilia and proceeding to lgE production and promotion can cause asthma (Barnes and Liew, 1995) . High concentration NO combined with superoxide (0+2) to produce the highly toxic peroxynitrite anions (OONO-) and hydroxyl radicals, which produce high oxidative stress and may damage airways epithelium and promote in lammation (Coleman, 2001) . For these reasons, it is likely that the selective inhibition of iNOS in asthma will result in decreased pulmonary in lammation and improved airway function. Increasing evidence in various animal models of asthma with either selective iNOS inhibitors or iNOS gene disruption supports this concept (Hansel and Barnes, 2001) . It may also promote glucocorticoids receptor bounding action, which will be a new pharmacological strategy for improving the ef icacy and therapeutic ratio of glucocorticoids in in lammatory lung diseases like chronic asthma. By cumu-lating all these above information, we select a speci ic INOS inhibitor (Aminoguanidine PO), which may produce an anti-asthmatic effect itself and may also contribute "Add-on Therapy" along with a low dosage of selective GR agonist (Dexamethasone, PO) in an ovalbumin-induced murine model of chronic asthma.
MATERIALS AND METHODS

Animals used
Female BALB/c mice of approximately 8 weeks aged were selected for this study. Animals were kept in the standard environmental condition speci ied by CPCSEA. Appropriate food and drinks were supplied to animals. Institutional Animal Ethics Committee (IAEC) reviewed the protocol and approved conducting this study.
STUDY DESIGN
The animals were acclimatized to experimental room conditions for 2 days before initiation of the study. They were divided into six groups (n=6) as per below. 
Group-1-Normal control
Experimental
Statistical analysis
Values for biochemical parameters were expressed as mean ± S.E.M. Statistical signi icance was calculated using one way ANOVA followed Dunnett's test.
RESULTS AND DISCUSSION
The WBC count in the normal animal was 0.262±0.5x103/µl while after OVA challenge it went up to 1.318±0.36 x103/µl. Oral administration of aminoguanidine, aminoguanidine with low dose of Dexamethasone (0.03mg/kg), Low dose of Dexamethasone (0.03mg/kg), and Dexamethasone (0.1mg/kg) treated showed WBC counts 0.732±0.09, 0.285±0.04, 0.399±0.036, Table 8 . Figure 1A) . Figure 2 shows the PAS staining. Figure 2B shows profound goblet cell hyperplasia (arrow sign indication) in the inner epithelium of alveoli (arrow sign indication). Still, there are no such cells in the normal control group (Figure 2A) . The combination effect of aminoguanidine plus a low dose of dexamethasone is showing complete resolving goblet cell hyperplasia in lungs ( Figure 2D ) like a high dose (0.1mg/kg) of dexamethasone. There are fewer amounts of goblet cells in Figure 2C & Figure 2E in compare to normal control. Figure 3A) . The combination effect of aminoguanidine plus a low dose of dexamethasone is shown complete resolving collagen deposition in lungs ( Figure 3D ) than the high dose (0.1mg/kg) of dexamethasone. There is less amount of goblet cells in Figure 3C & Figure 3E in comparison to the normal control.
HISTOPATHOLOGICAL EVALUATION
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In the present study, we investigated the effect of aminoguanidine and dexamethasone in a model of the allergen (OVA) induced asthma in mice. In this study, we have shown that the OVA challenge in mice induces a signi icant elevation of WBC in the BALF. The Ova challenge resulted in excess production of neutrophils and eosinophils associated with key in lammatory cytokines, including TNF-α, IL-6 and IFN-γ in BALF. Our indings support several earlier studies that have demonstrated the accumulation of eosinophils and neutrophils and an increase of pro-in lammatory cytokines levels in the airways and BALF (Sr, 2007; Kharitonov et al., 1996) . The indings of this research revealed that cytokines levels were signi icantly decreased in combinationtreated animals with respect to alone dexamethasone treatments, which may be due to the synergistic effect of aminoguanidine and dexamethasone. The pharmacological mechanism of this synergistic effect may be due to the elevation of HDAC2 activity in combination-treated animals than OVA control animals (Ito et al., 2005) . Especially IL-6 level was signi icantly decreased in combination-treated animals, but interestingly IL-6 level was increased in a high dose of dexamethasone-treated animals. It was observed that both aminoguanidine and dexamethasone as monotherapy signi icantly decreased total count and eosinophil counts in the BAL luid. However, no signi icant change in cell count was observed in the combination treatment group in comparison to single treatments. Histopathological data showed combination treatment completely resolves the in iltrating in lammatory cells into the lungs. Furthermore, combination treatment could able to reduce goblet cell hyperplasia and collagen deposition in lamina propria of alveoli. In iltration of in lammatory cells can cause structural changes includes sub-epithelial ibrosis in asthmatic airways. The in iltration of in lammatory cells, goblet cell hyperplasia and collagen deposition, are closely associated with the level of cytokines (Wen et al., 2003; Riffo-Vasquez and Spina, 2002) , which was markedly inhibited by this combination therapy than OVA control group.
CONCLUSIONS
By cumulating all the indings of current research, this pre-clinical study concluded that combination treatment of aminoguanidine and dexamethasone showed better recovery of lung in lammation and remodeling in asthmatic animals which is a new pharmacological strategy for improving the ef icacy and therapeutic ratio of glucocorticoids in in lammatory lung diseases like chronic asthma. This study may enlighten a novel combination therapy to ameliorate asthma and other in lammatory lung diseases like COPD, which needs further clinical investigation.
